Pramipexole

• UNSPSC Description:

  Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS)[1][2][3].

• Target Antigen:

  Dopamine Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/pramipexole.html

• Purity:

  99.95

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  NC1=NC(CC[C@H](NCCC)C2)=C2S1

• Molecular Weight:

  211.334

• References & Citations:

  [1]Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78.|[2]Takashi Okura, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007 Apr 3;80(17):1564-71.|[3]Ginetta Collo, et al. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018; 2018: 4196961.|[4]P M Carvey, et al. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm (Vienna). 1997;104(2-3):209-28.|[5]Syed Suhail Andrabi, et al. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019 Aug 1; 12(8): dmm033860.Neurochem Int. 2021 Jan 22;104972.|Prog Neurobiol. 2023 Oct 5:102536.|J Affect Disord. 2024 Apr 22:356:586-596.|J Stroke Cerebrovasc Dis. 2023 Apr 25;32(7):107142.|J Stroke Cerebrovasc Dis. 2024 Oct 26:108101.|PeerJ. 2023 Sep 11.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  104632-26-0